Please select the option that best describes you:
Topics:
Hematologic Malignancies • Pediatric Hematology/Oncology • Medical Oncology • Lymphoma • Hematology
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
Would you consider holding, deferring, or skipping treatment?
For hepatitis, how would determine if toxicity was immunotherapy vs chemotherapy related?